The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Empath Biosciences; Karyopharm Therapeutics; Ryvu Therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; Karyopharm Therapeutics; Rigel; Ryvu Therapeutics; Treadwell Therapeutics
Research Funding - Astex Pharmaceuticals; Incyte; Taiho Oncology
Patents, Royalties, Other Intellectual Property - Empath Bioscience
Travel, Accommodations, Expenses - Ryvu Therapeutics; Taiho Oncology
An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts.
 
Amer Zeidan
Honoraria - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Consulting or Advisory Role - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; Astex Pharmaceuticals; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Research Funding - Abbvie (Inst); Amgen; Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Geron; Kura Oncology; Novartis (Inst); Otsuka; Shattuck Labs; Syros Pharmaceuticals; Takeda (Inst)
 
Elizabeth Griffiths
Honoraria - AAMDSIF; American Society of Hemotology; Medicom Worldwide; Physician Educational Resource; PicnicHealth
Consulting or Advisory Role - Abbvie; Alexion/AstraZeneca Rare Disease; Apellis Pharmaceuticals; Bristol-Myers Squibb/Celgene; CTI BioPharma Corp; Genentech; Novartis; SERVIER; Takeda
Research Funding - Alexion/AstraZeneca Rare Disease; Astex Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Celldex; Genentech; Taiho Oncology
 
Courtney Dinardo
Honoraria - Abbvie; Astellas Pharma; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; Genentech/Abbvie; GlaxoSmithKline; Schrodinger; SERVIER
Consulting or Advisory Role - Abbvie; AstraZeneca; Genmab; Molecular Partners; Rigel; Ryvu Therapeutics; Schrodinger; SERVIER
Research Funding - Abbvie; Astex Pharmaceuticals; BeiGene; Bristol-Myers Squibb/Celgene; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Jazz Pharmaceuticals; Loxo/Lilly; Remix Therapeutics; SERVIER
 
Gabriel Mannis
Consulting or Advisory Role - Abbvie/Genentech; Astellas Pharma; Bristol-Myers Squibb/Celgene; Immunogen; Macrogenics; Orbital Therapeutics; Rigel; SERVIER; Stemline Therapeutics; Syndax; WUGEN, Inc.
Research Funding - Astex Pharmaceuticals (Inst); Bristol-Myers Squibb/Celgene (Inst); Forty Seven (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Immune-Onc Therapeutics (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Syndax (Inst)
 
Pau Montesinos
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Jazz Pharmaceuticals; Otsuka; Pfizer; SERVIER
Speakers' Bureau - Celgene; Daiichi Sankyo; Otsuka
Research Funding - Abbvie (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen-Cilag (Inst); Pfizer (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen
 
Montserrat Arnan
Consulting or Advisory Role - Abbvie; Jazz Pharmaceuticals
Speakers' Bureau - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Jazz Pharmaceuticals; Otsuka
Travel, Accommodations, Expenses - Abbvie; Jazz Pharmaceuticals
 
Michael Savona
No Relationships to Disclose
 
Olatoyosi Odenike
Consulting or Advisory Role - Abbvie; Blueprint Medicines; BMS; Bristol-Myers Squibb/Celgene (Inst); Celgene; CTI; Impact Biomedicines; Kymera; Novartis; SERVIER; Taiho Pharmaceutical; Threadwell therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Aprea AB (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CTI BioPharma Corp (Inst); Daiichi Sankyo (Inst); Incyte (Inst); Janssen Oncology (Inst); Kartos Therapeutics (Inst); Loxo (Inst); Novartis (Inst); NS Pharma (Inst); OncoTherapy Science (Inst)
 
James McCloskey
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; CTI; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals; PharmaEssentia; Taiho Oncology; Takeda
 
Harsh Amin
No Relationships to Disclose
 
Amir Fathi
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; Foghorn Therapeutics; Genentech; Kite, a Gilead Company
Research Funding - Abbvie; Agios; Celgene/Bristol-Myers Squibb; SERVIER
 
Teresa Bernal del Castillo
Consulting or Advisory Role - Abbvie; Astellas Pharma; Jazz Pharmaceuticals
Speakers' Bureau - Abbvie
Research Funding - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Gabriela Rodriguez-Macias
Consulting or Advisory Role - Abbvie; Astellas Pharma; Jazz Pharmaceuticals; Otsuka; SERVIER
Speakers' Bureau - Abbvie; Astellas Pharma; Jazz Pharmaceuticals; Otsuka
Travel, Accommodations, Expenses - Abbvie; Jazz Pharmaceuticals; SERVIER
 
Jane Liesveld
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb Foundation/Janssen; Pharmacosmos
Other Relationship - Onconova Therapeutics; Syros Pharmaceuticals
 
Annie Im
Stock and Other Ownership Interests - CytoAgents (I); Duo Oncology
Consulting or Advisory Role - Abbvie; CTI BioPharma Corp; Incyte
Speakers' Bureau - Incyte
Research Funding - Incyte
Travel, Accommodations, Expenses - Incyte
 
Aram Oganesian
Employment - Taiho Oncology
 
Qing Xu
Employment - Taiho Oncology
Leadership - Taiho Oncology
 
Margit Dijkstra
Employment - Taiho Oncology
 
Harold Keer
Employment - Taiho Oncology
 
Gail Roboz
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Caribou Biosciences; Celgene; Daiichi Sankyo; Ellipses Pharma; Genentech/Roche; Geron; GlaxoSmithKline; Janssen; Jasper Therapeutics; Jazz Pharmaceuticals; MorphoSys; NeoGenomics Laboratories; Novartis; Oncoprecision; Oncoverity; Pfizer; Rigel; Roche; Syndax; Takeda
Research Funding - Abbvie (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Cellectis (Inst); CTI (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Moffitt (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb/Celgene; Janssen; Jazz Pharmaceuticals; Novartis; Roche/Genentech